Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • ROOMS:

Apollomics Enters $189 Million Deal for China Rights to Two GlycoMimetics Immunotherapies

Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia. Apollomics, which was incubated by OrbiMed Asia, will be responsible for developing uproleselan and GMI-1687 in mainland China, Hong Kong, Macau and Taiwan. GlycoMimetics will receive a $9 million upfront payment and be eligible for up to $180 million in milestones plus royalties. Apollomics is developing five assets: two novel mAbs that restore the body’s immune system along with three therapies that target growth signaling pathways. More details.... Stock Symbols: (NSDQ: GLYC) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.